However, the deal would face strong headwinds in getting regulators' approval at the Justice Department and the FCC.

But getting regulators to allow the company to fund more of its businesses with deposits has taken time, analysts said.

But even if they succeed, manufacturing in bulk, getting regulators to sign off and packaging billions of doses is a monumental challenge.

Goldman would likely focus on getting regulators to back off civil fraud charges, and agree to lesser charges and a fine, the report said.

Goldman would likely focus on getting regulators to back off civil fraud charges, and instead agree to lesser charges and a fine, the report said.